Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MadeMed vs MyDrHank

By GLP-1 ScorecardUpdated

MadeMed
Site position #35

Higher score

MyDrHank
Site position #105

Lower score

Score comparison

MadeMed has the higher recorded score — 80.4/100 to 68.2/100.

MadeMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MadeMed advertises all-dose pricing across 30-, 90- and 360-day purchases, with a consultation-fee conflict to resolve before prepaying.

Before you choose

Before comparing the headline prices, the MadeMed review and the MyDrHank review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, MadeMed vs Näky and MyDrHank vs No BS RX compare each of them with another graded program, and the list of alternatives to MadeMed ranks the programs closest to MadeMed on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueMadeMed +4
74
70
Dose & formulationMadeMed +6
90
84
Clinical oversightMadeMed +18
84
66
Labs & monitoringMadeMed +12
62
50
FulfillmentMadeMed +12
90
78
Contract termsMadeMed +40
88
48
MadeMed · top barMyDrHank · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricMadeMedMyDrHank
WeighScore80.4/10068.2/100
GradeB−C
Site position#35#105
Semaglutide$179 every 30 days; $483/90 days or $1,718/360 days ($143.17 equivalent per 30 days); consultation fees and usable supply require confirmationFrom $171/mo oral or injectable on GLP-1 lander; injection product page from $178/mo (conflicting offer terms; confirm)
TirzepatideInjection or sublingual: $249 every 30 days; $672/90 days or $2,390/360 days ($199.17 equivalent per 30 days); final fees and supply unverifiedFrom $200/mo on GLP-1 lander; product page from $240/mo (conflicting offer terms; confirm)
CoverageConfirm selected treatment/state: sublingual tirzepatide FAQ lists 40 states; current injection-state map unverifiedConfirm prescription and state; contiguous-U.S. shipping claim does not establish individual eligibility
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesYes
MadeMed

Site position #35 · B−

Strengths

  • Public selectors show full charges for 30-, 90- and 360-day plans across the listed GLP-1 products
  • Advertises the same pricing across doses, ongoing clinical messaging and included injection supplies
  • Current terms name MDI Medical Group PC and four partner pharmacy brands
  • A 30-day purchase is advertised alongside the larger prepaid options

What to consider

  • Lowest advertised equivalents require $1,718/$2,390 360-day billing plans; terms reject prorated refunds
  • Product pages list $20/$30 consultation fees while How It Works says consultation is included and ineligible payments are refunded in full
  • The forty-state claim is specific to sublingual tirzepatide; an injection-state map was not established
  • Assigned clinician/pharmacy branch, patient lab costs, final first debit and usable prescription supply remain unresolved
MyDrHank

Site position #105 · C

Strengths

  • Public landing and product pages show starting prices before medical intake
  • Compounded injection options and a separate oral semaglutide menu are advertised, with formulation differences to discuss with the prescriber
  • Product pages advertise consultation, delivery, check-ins and unlimited clinical messaging; response times were not tested
  • Terms identify the platform operator and offer the current pharmacy-partner list on request

What to consider

  • The GLP-1 lander shows $171/$200 injectable starting rates, while separate injection pages show $178/$240; applicable purchase terms remain unresolved
  • Published base plan fields do not establish that a particular promotion is unavailable or what an individual will actually pay
  • The reviewed GLP-1 terms did not establish the cancellation cutoff, unused-prepayment refund formula or declined-treatment financial outcome
  • The assigned medical practice, prescriber and dispensing location remain unestablished; no current individual license verification is claimed
  • Dose, concentration, usable supply, laboratory costs and state-specific availability require confirmation
  • Compounded preparations are not FDA-approved; displayed branded-product trial results do not establish outcomes for these formulations

Featured provider

MyDrHank

MyDrHank scores 68.2/100 (C). MyDrHank advertises compounded tablets and injections, but its GLP-1 landing page and separate product pages show different starting prices; get one written offer before choosing a term.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard